Drug intelligence / Profile preview

NEU001

Development stage: Unknown
Lead developer: NeuCen BioMed
Administration: Intraperitoneal, Intravenous, Intramuscular, Subcutaneous, Rectal

Overview

NEU001 is an investigational drug candidate developed by NeuCen BioMed. It was being advanced for the treatment of nasopharyngeal carcinoma and was slated for Phase II clinical studies in the U.S. The clinical development was managed by BioKey, a subsidiary of ABVC BioPharma, through a clinical services agreement that was subsequently terminated due to unresolved loan agreement terms.

Targets

ELANE (Human Neutrophil Elastase)

Beyond the preview

Go deeper on NEU001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NEU001.

Explore the full profile